This study reports a previously unexamined therapeutic effect of TanCAR-T cells in NSCLC, providing a preclinical rationale for combining anti-PD-1 antibodies with TanCAR-T cells targeting MUC1 and PSCA in NSCLC treatment (16). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.